- Home
- HLVX vs CPIX Comparison
HLVX vs CPIX Comparison
Compare HLVX & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- CPIX
- Stock Information
- Founded
- HLVX 2020
- CPIX 1999
- Country
- HLVX United States
- CPIX United States
- Employees
- HLVX N/A
- CPIX N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- CPIX Biotechnology: Pharmaceutical Preparations
- Sector
- HLVX Health Care
- CPIX Health Care
- Exchange
- HLVX Nasdaq
- CPIX Nasdaq
- Market Cap
- HLVX 83.7M
- CPIX 68.7M
- IPO Year
- HLVX 2022
- CPIX 2009
- Fundamental
- Price
- HLVX $1.90
- CPIX $4.70
- Analyst Decision
- HLVX Hold
- CPIX
- Analyst Count
- HLVX 5
- CPIX 0
- Target Price
- HLVX $2.33
- CPIX N/A
- AVG Volume (30 Days)
- HLVX 295.3K
- CPIX 21.7K
- Earning Date
- HLVX 05-08-2025
- CPIX 05-06-2025
- Dividend Yield
- HLVX N/A
- CPIX N/A
- EPS Growth
- HLVX N/A
- CPIX N/A
- EPS
- HLVX N/A
- CPIX N/A
- Revenue
- HLVX N/A
- CPIX $41,083,299.00
- Revenue This Year
- HLVX N/A
- CPIX N/A
- Revenue Next Year
- HLVX N/A
- CPIX N/A
- P/E Ratio
- HLVX N/A
- CPIX N/A
- Revenue Growth
- HLVX N/A
- CPIX 5.82
- 52 Week Low
- HLVX $1.34
- CPIX $1.04
- 52 Week High
- HLVX $16.31
- CPIX $7.25
- Technical
- Relative Strength Index (RSI)
- HLVX 60.50
- CPIX 52.45
- Support Level
- HLVX $1.81
- CPIX $4.32
- Resistance Level
- HLVX $1.94
- CPIX $4.86
- Average True Range (ATR)
- HLVX 0.10
- CPIX 0.34
- MACD
- HLVX 0.00
- CPIX -0.02
- Stochastic Oscillator
- HLVX 79.31
- CPIX 36.89
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About CPIX Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.